Decreasing plasma soluble IL-1 receptor antagonist and increasing monocyte activation early post-transplant may be involved in pathogenesis of delayed graft function in renal transplant recipients

Clinical Transplantation

Volumn 24, Issue 3, 2010, Pages 415-423

  Sadeghi, Mahmoud ^a   Daniel, Volker ^a   Naujokat, Cord ^a   Schmidt, Jan ^a   Mehrabi, Arianeb ^a   Zeier, Martin ^a   Opelz, Gerhard ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Delayed graft function; Monocyte activation; Monokine; Plasma cytokines; Renal transplantation; SIL 1RA

Indexed keywords

CREATININE; CYTOKINE RECEPTOR ANTAGONIST; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 6 RECEPTOR; NEOPTERIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6;

ADULT; ARTICLE; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; DELAYED GRAFT FUNCTION; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; MONOCYTE; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RECEPTOR BLOCKING; BLOOD; GRAFT REJECTION; GRAFT SURVIVAL; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME;

CREATININE; DELAYED GRAFT FUNCTION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-6; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MONOCYTES; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-6; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 77954171071     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.01130.x     Document Type: Article

References (41)

1. Szwarc I, Garrigue V, Delmas S, Deleuze S, Chong G, Mourad G. Delayed graft function: a frequent but still unsolved problem in renal transplantation. Nephrol Ther 2005, 1:325.
2. Molls RR, Savransky V, Liu M. Keratinocyte-derived chemokine is an early biomarker of ischemic acute kidney injury. Am J Physiol Renal Physiol 2006, 290:F1187.
3. Rodrigo E, Ruiz JC, Piñera C. Creatinine reduction ratio on posttransplant day two as criterion in defining delayed graft function. Am J Transplant 2004, 4:1163.
4. Boom H, Mallat MJ, de Fijter JW, Zwinderman AH, Paul LC. Delayed graft function influences renal function, but not survival. Kidney Int 2000, 58:859.
5. Tejani AH, Sullivan EK, Alexander SR, Fine RN, Harmon WE, Kohaut EC. Predictive factors for delayed graft function (DGF) and its impact on renal graft survival in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1999, 3:293.
6. Perez Fontan M, Rodriguez-Carmona A, Bouza P, Valdes F. The prognostic significance of acute renal failure after renal transplantation in patients treated with cyclosporin. QJM 1998, 91:27.
7. Marcen R, Orofino L, Pascual J. Delayed graft function does not reduce the survival of renal transplant allografts. Transplantation 1998, 66:461.
8. Ojo AO, Wolfe RA, Held PJ, Port FK, Schmouder RL. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation 1997, 63:968.
9. Takada M, Nadeau KC, Shaw GD, Tilney NL. Prevention of late renal changes after initial ischemia/reperfusion injury by blocking early selectin binding. Transplantation 1997, 64:1520.
10. Oda A, Morozumi K, Uchida K. Histological factors of 1-h biopsy influencing the delayed renal function and outcome in cadaveric renal allografts. Clin Transplant 1999, 13(Suppl 1):6.
11. Parzanese I, Maccarone D, Caniglia L. Risk factors that can influence kidney transplant outcome. Transplant Proc 2006, 38:1022.
12. Thorne-Tjomsland G, Hosfield T, Jamieson JC. Increased levels of GALbeta1-4GLCNACalpha2-6 sialyltransferase pretransplant predict delayed graft function in kidney transplant recipients. Transplantation 2000, 69:806.
13. McLaren AJ, Jassem W, Gray DW, Fuggle SV, Welsh KI, Morris PJ. Delayed graft function: risk factors and the relative effects of early function and acute rejection on long-term survival in cadaveric renal transplantation. Clin Transplant 1999, 13:266.
14. Lechevallier E, Dussol B, Luccioni A. Posttransplantation acute tubular necrosis: risk factors and implications for graft survival. Am J Kidney Dis 1998, 32:984.
15. Daniel V, Pasker S, Wiesel M. Cytokine monitoring of infection and rejection in renal transplant recipients. Transplant Proc 1995, 27:884.
16. Cecka JM. The UNOS Scientific Renal Transplant Registry. Clin Transplant 1998, 12:1.
17. Basar H, Soran A, Shapiro R. Renal transplantation in recipients over the age of 60: the impact of donor age. Transplantation 1999, 67:1191.
18. Lebranchu Y, Halimi JM, Bock A. Delayed graft function: risk factors, consequences and parameters affecting outcome-results from MOST, A Multinational Observational Study. Transplant Proc 2005, 37:345.
19. Van Biesen W, Vanholder R, Van Loo A, Van Der Vennet M, Lameire N. Peritoneal dialysis favourably influences early graft function after renal transplantation compared to hemodialysis. Transplantation 2000, 9:508.
20. Hoffmann SC, Kampen RL, Amur S. Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia-reperfusion injury. Transplantation 2002, 74:916.
21. Wiggins MC, Bracher M, Mall A, Hickman R, Robson SC, Kahn D. Tumour necrosis factor levels during acute rejection and acute tubular necrosis in renal transplant recipients. Transpl Immunol 2000, 8:211.
22. Raasveld MH, Bloemena E, Wilmink JM, Surachno S, Schellekens PT, ten Berge RJ. Interleukin-6 and neopterin in renal transplant recipients: a longitudinal study. Transpl Int 1993, 6:89.
23. Sadeghi M, Daniel V, Naujokat C, Mehrabi A, Opelz G. Association of high pretransplant sIL-6R plasma levels with acute tubular necrosis in kidney graft recipients. Transplantation 2006, 81:1716.
24. Schäfer AJ, Daniel V, Dreikorn K, Opelz G. Assessment of plasma neopterin in clinical kidney transplantation. Transplantation 1986, 41:454.
25. Lauzurica R, Pastor MC, Bayés B. Pretransplant inflammation: a risk factor for delayed graft function? J Nephrol 2008, 21:221.
26. Dinarello CA. Reduction of inflammation by decreasing production of interleukin-1 or by specific receptor antagonism. Int J Tissue React 1992, 14:65.
27. Yang H, Tüzün E, Alagappan D. IL-1 receptor antagonist-mediated therapeutic effect in murine myasthenia gravis is associated with suppressed serum proinflammatory cytokines, C3, and anti-acetylcholine receptor IgG1. J Immunol 2005, 175:2018.
28. Oliveira JG, Xavier P, Neto S, Mendes AA, Guerra LE. Monocytes-macrophages and cytokines/chemokines in fine-needle aspiration biopsy cultures: enhanced interleukin-1 receptor antagonist synthesis in rejection-free kidney transplant patients. Transplantation 1997, 63:1751.
29. Manchanda PK, Bid HK, Kumar A, Mittal RD. Genetic association of interleukin-1beta and receptor antagonist (IL-1Ra) gene polymorphism with allograft function in renal transplant patients. Transpl Immunol 2006, 15:289.
30. Teppo AM, Honkanen E, Ahonen J, Grönhagen-Riska C. Does increased urinary interleukin-1 receptor antagonist/interleukin-1beta ratio indicate good prognosis in renal transplant recipients? Transplantation 1998, 66:1009.
31. Sadeghi M, Daniel V, Weimer R, Wiesel M, Hergesell O, Opelz G. Differential early posttransplant cytokine responses in living and cadaver donor renal allografts. Transplantation 2003, 75:1351.
32. Scheller J, Ohnesorge N, Rose-John S. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol 2006, 63:321.
33. Memoli B, Postiglione L, Cianciaruso B. Role of different dialysis membranes in the release of interleukin-6-soluble receptor in uremic patients. Kidney Int 2000, 58:417.
34. Girndt M, Kaul H, Leitnaker CK, Sester M, Sester U, Köhler H. Selective sequestration of cytokine-producing monocytes during hemodialysis treatment. Am J Kidney Dis 2001, 37:954.
35. Belardelli F. Role of interferons and other cytokines in the regulation of the immune response. APMIS 1995, 103:161.
36. Maynard CL, Weaver CT. Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation. Immunol Rev 2008, 226:219.
37. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol 1993, 11:165.
38. Fuchs D, Weiss G, Reibnegger G, Wachter H. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci 1992, 29:307.
39. Grebe SO, Mueller TF. Immune monitoring in organ transplantation using neopterin. Curr Drug Metab 2002, 3:189.
40. Fuchs D, Stahl-Hennig C, Gruber A, Murr C, Hunsmann G, Wachter H. Neopterin - its clinical use in urinalysis. Kidney Int Suppl 1994, 47:S8.
41. Kotanko P, Margreiter R, Pfaller W. Urinary N-acetyl-beta-d-glucosaminidase and neopterin aid in the diagnosis of rejection and acute tubular necrosis in initially nonfunctioning kidney grafts. Nephron 2000, 84:228.